Fosnetupitant

Chemical compound

None

IdentifiersCAS Number

1703748-89-3

PubChem CID

71544786

DrugBank

DB14019

ChemSpider

44208829

UNII

T672P80L2S

KEGG

D11065

ChEMBL

ChEMBL3989917

CompTox Dashboard (EPA)

DTXSID601027641

Chemical and physical dataFormulaC₃₁H₃₅F₆N₄O₅PMolar mass688.608 g·mol⁻¹

Fosnetupitant is a medication used for the treatment of chemotherapy-induced nausea and vomiting. It is a prodrug of netupitant.^[1] It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use.^[2]

In 2018, the US Food and Drug Administration approved the intravenous formulation of a fixed dose combination of fosnetupitant and palonosetron.^[3]^[4] The combination is also approved for medical use in the European Union,^[5] and in Canada.^[6]

References

^ Aapro M, Jordan K, Scotté F, Celio L, Karthaus M, Roeland E (2022). "Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice". Current Cancer Drug Targets. 22 (10): 806–824. doi:10.2174/1568009622666220513094352. PMC 9720881. PMID 35570542.
^ "Fosnetupitant/Palonosetron (Intravenous Route)". Mayo Clinic. Archived from the original on 8 June 2022. Retrieved 8 June 2022.
^ "Fosnetupitant". DrugBank. Archived from the original on 2 December 2021. Retrieved 8 June 2022.
^ "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020.
^ "Akynzeo EPAR". European Medicines Agency (EMA). 23 June 2015. Archived from the original on 19 March 2020. Retrieved 9 June 2022.
^ "Akynzeo (netupitant/palonosetron) capsules" (PDF). Product Insert. Elvium Life Sciences. 31 August 2020. Archived (PDF) from the original on 10 June 2022. Retrieved 10 June 2022.